76 related articles for article (PubMed ID: 7774853)
1. Onycholysis of the finger and toenails following the application of high-dose oral etoposide (1250 mg/m2) given as 200- and 150-mg single doses from days 1-10 every 3 weeks.
Obermair A; Vavra N; Kurz C; Helmer H; Sevelda P; Pehamberger K
Gynecol Oncol; 1995 Jun; 57(3):436. PubMed ID: 7774853
[No Abstract] [Full Text] [Related]
2. Granulocyte-macrophage colony-stimulating factor given before dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP).
Holdsworth MT; Roon R; Ferguson J; Martinez L; Stidley CA; Neidhart JA
Biotechnol Ther; 1993; 4(3-4):183-95. PubMed ID: 8292969
[TBL] [Abstract][Full Text] [Related]
3. Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating-factor support for dose-intensive cyclophosphamide, etoposide, and cisplatin.
Yau JC; Neidhart JA; Triozzi P; Verma S; Nemunaitis J; Quick DP; Mayernik DG; Oette DH; Haynes FA; Holcenberg J
Am J Hematol; 1996 Apr; 51(4):289-95. PubMed ID: 8602629
[TBL] [Abstract][Full Text] [Related]
4. [A pilot trial of high dose CEP (cyclophosphamide, epirubicin, cis-platinum) therapy in patients with advanced and recurrent ovarian cancer].
Hiura M; Ogawa M; Nozawa S; Kudo R; Kuwabara Y; Takahashi T; Takayama M; Tateno M; Ohashi Y; Yakushiji M
Gan To Kagaku Ryoho; 2000 Apr; 27(4):585-91. PubMed ID: 10791001
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer.
Tung N; Berkowitz R; Matulonis U; Quartulli M; Seiden M; Kim Y; Niloff J; Cannistra SA
Gynecol Oncol; 2000 May; 77(2):271-7. PubMed ID: 10785477
[TBL] [Abstract][Full Text] [Related]
6. The impact of schedule on acute toxicity and dose-intensity of high-dose chemotherapy with epirubicin and cyclophosphamide plus colony stimulating factors in advanced breast cancer.
De Placido S; Lauria R; Carlomagno C; Perrone F; De Laurentiis M; Gallo C; Martignetti A; Bellelli T; Limite G; Petrella G; Bianco AR
Int J Oncol; 1999 Aug; 15(2):339-46. PubMed ID: 10402245
[TBL] [Abstract][Full Text] [Related]
7. A new schedule for etoposide, epidoxorubicin and cisplatin with granulocyte colony stimulating factor for advanced gastric cancer: a feasibility study.
Pronzato P; Vigani A; Pensa F; Botto F; Ghio E; Neri E; Tognoni A; Vaira F
Anticancer Res; 1997; 17(5B):3873-6. PubMed ID: 9427795
[TBL] [Abstract][Full Text] [Related]
8. Prophylactic granulocyte colony-stimulating factor allows escalation of chemotherapeutic dose intensity in advanced epithelial ovarian cancer.
Fanning J; Hilgers RD
Gynecol Oncol; 1996 Dec; 63(3):323-7. PubMed ID: 8946866
[TBL] [Abstract][Full Text] [Related]
9. High-dose carboplatin, cyclophosphamide, etoposide with hematological growth factors, without stem cell support in patients with advanced cancer.
Recchia F; De Fillipis S; Piccinini M; Rea S
Anticancer Res; 2003; 23(5b):4141-7. PubMed ID: 14666615
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial with pharmacokinetic analyses of high-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in patients with refractory germ cell tumors.
Motzer RJ; Gulati SC; Tong WP; Menendez-Botet C; Lyn P; Mazumdar M; Vlamis V; Lin S; Bosl GJ
Cancer Res; 1993 Aug; 53(16):3730-5. PubMed ID: 8393380
[TBL] [Abstract][Full Text] [Related]
11. Sequential high dose-density chemotherapy with two active regimens for advanced small cell lung cancer.
Vigani A; Pensa F; Vaira F; Bancalari L; Cordani S; Maggiani R; Canessa P; Pronzato P
Anticancer Res; 2000; 20(5C):4015-8. PubMed ID: 11268494
[TBL] [Abstract][Full Text] [Related]
12. A Phase I study of granulocyte-macrophage-colony stimulating factor/interleukin-3 fusion protein (PIXY321) following ifosfamide, carboplatin, and etoposide therapy for children with recurrent or refractory solid tumors: a report of the Children's Cancer Group.
Cairo MS; Krailo MD; Weinthal JA; Secola R; Bergeron S; van de Ven C; Blazar BR; Garrison L; Reaman GH
Cancer; 1998 Oct; 83(7):1449-60. PubMed ID: 9762948
[TBL] [Abstract][Full Text] [Related]
13. Sequential high dose-density chemotherapy in advanced ovarian cancer.
Tognoni A; Pronzato P; Cadenotti L; Ghio E; Manna N; Pensa F; Marino L
Anticancer Res; 2000; 20(5C):3957-61. PubMed ID: 11268483
[TBL] [Abstract][Full Text] [Related]
14. [Mobilization of peripheral blood stem cells in advanced ovarian cancer].
Terasawa K; Sagae S; Mizumoto H; Iwasaki M; Kudo R
Gan To Kagaku Ryoho; 1998 Sep; 25(11):1731-7. PubMed ID: 9757199
[TBL] [Abstract][Full Text] [Related]
15. Sequential interleukin-3 and granulocyte-colony stimulating factor prior to and following high-dose etoposide and cyclophosphamide: a phase I/II trial.
Bernstein SH; Fay JP; Christiansen NP; Pinero L; Shah D; Stephan M; Herzig GP
Clin Cancer Res; 1997 Sep; 3(9):1519-26. PubMed ID: 9815838
[TBL] [Abstract][Full Text] [Related]
16. Escalating high-dose epirubicin plus cisplatin in small cell lung cancer with granulocyte-macrophage colony-stimulating factor use when appropriate.
Rosell R; Gómez-Codina J; Anton A; Sánchez JJ; Vadell C
Semin Oncol; 1994 Feb; 21(1 Suppl 1):48-53. PubMed ID: 8153657
[No Abstract] [Full Text] [Related]
17. A randomized phase I trial of chronic oral etoposide with or without granulocyte-macrophage colony-stimulating factor in patients with advanced malignancies.
Shaffer DW; Smith LS; Burris HA; Clark GM; Eckardt JR; Fields SM; Weiss GR; Rinaldi DA; Bowen KJ; Kuhn JG
Cancer Res; 1993 Dec; 53(24):5929-33. PubMed ID: 8261405
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of high-dose cisplatin, etoposide, and cyclophosphamide for refractory ovarian cancer.
Cain JM; Collins C; Petersdorf S; Figge DC; Tamimi HK; Greer BE; Livingston RB
Am J Obstet Gynecol; 1996 Jun; 174(6):1688-94; discussion 1694. PubMed ID: 8678128
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
Kelly K; Pan Z; Wood ME; Murphy J; Bunn PA
Clin Cancer Res; 1999 Nov; 5(11):3419-24. PubMed ID: 10589753
[TBL] [Abstract][Full Text] [Related]
20. Etoposide, cisplatin, epirubicin chemotherapy in the treatment of pediatric liver tumors.
Casanova M; Massimino M; Ferrari A; Spreafico F; Piva L; Coppa J; Luksch R; Cefalo G; Terenziani M; Polastri D; Bellani FF; Mazzaferro V
Pediatr Hematol Oncol; 2005; 22(3):189-98. PubMed ID: 16020101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
